Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shireen Guide

Pediatric Dermatology Palo Alto, CA Medical Doctor

NPI 1033287180 CMS profile 274051

725 Welch Rd, Palo Alto, CA 94304

Open in the dashboard

General payments

$40,595

297 records reported · program years 2019–2025

Research payments

$41,440

Paid to them · 20 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$528,299 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Shireen Guide of Palo Alto, CA is reported in the CMS Open Payments database as having received $40,595 across 297 general payments and $41,440 in research payments paid to them. Separately, studies naming them as principal investigator received $528,299 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,203 65
2024 General $4,518 26
2024 Research $10,991 6
2023 General $26,481 63
2023 Research $30,449 14
2022 General $1,107 42
2021 General $869 37
2020 General $399 17
2019 General $1,018 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shireen Guide
  • Pediatric Dermatology median
  • Middle half of Pediatric Dermatology
  • National median

In program year 2025, general payments to Shireen Guide were reported at $6,203. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.

Show as a table
Year Shireen Guide Pediatric Dermatology median Middle half National median
2019 $1,018 $280 $89–$1,853 $163
2020 $399 $263 $71–$2,376 $114
2021 $869 $227 $69–$1,800 $132
2022 $1,107 $289 $69–$1,516 $149
2023 $26,481 $537 $114–$3,255 $160
2024 $4,518 $437 $114–$2,693 $164
2025 $6,203 $302 $110–$2,128 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Krystal Biotech Inc $30,662 30 payments
  2. Novartis Pharmaceuticals Corporation $3,465 32 payments
  3. Pfizer Inc. $939 49 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $745 11 payments
  5. Genzyme Corporation $634 19 payments
  6. Incyte Corporation $593 25 payments
  7. AbbVie, Inc. $534 24 payments
  8. Regeneron Healthcare Solutions, Inc. $445 15 payments
  9. Solta Medical, a division of Bausch Health US, LLC $234 3 payments
  10. Chiesi USA, Inc. $225 5 payments
  11. Other $2,117 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,800 7 payments
  2. Consulting Fee $9,875 4 payments
  3. Food and Beverage $7,042 274 payments
  4. Travel and Lodging $3,615 6 payments
  5. Education $262 6 payments
Products named General payments · program years 2019–2025
  1. VYJUVEK $23,662 28 payments
  2. VIJOICE $2,728 2 payments
  3. EUCRISA $536 36 payments
  4. OPZELURA $498 24 payments
  5. DUPIXENT Immunology $484 19 payments
  6. CIBINQO $428 25 payments
  7. RINVOQ $417 18 payments
  8. DUPIXENT Inflammation And Immunology $380 13 payments
  9. COSENTYX $252 11 payments
  10. LITFULO $243 11 payments
  11. Other $3,780 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Arcutis Biotherapeutics, Inc. $41,440 20 payments

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

339

Median for Dermatology: 534

Drug cost

$2,037,369

Median for Dermatology: $67,151

Branded share of claims

29.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyjuvek Beremagene Geperpavec-Svdt Brand 86 $2,007,559
Opzelura Ruxolitinib Phosphate Brand 13 $25,577
Ketoconazole Generic 68 $1,008
Fluorouracil Generic 15 $818
Tacrolimus Generic 11 $808
Fluocinonide Generic 19 $612
Triamcinolone Acetonide Generic 53 $453
Minoxidil Generic 34 $323
Cephalexin Generic 17 $142
Finasteride Generic 23 $69

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$204,018

Of which drugs: $2,729

Medicare patients

304

Average age 74

Services billed

5,156

180 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 44%
Ischemic heart disease 20%
Osteoporosis 17%
Diabetes 16%
Depression 16%
Cancer 15%
Chronic kidney disease 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fluorouracil, 500 mg J9190 Office 20 27 $63
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 15 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYJUVEK
  • Krystal Biotech Inc $3,661
$3,661 86 —
DUPIXENT
  • GENZYME CORPORATION $42
  • Regeneron Healthcare Solutions, Inc. $34
$76 — —
RINVOQ
  • AbbVie, Inc. $74
$74 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $67
$67 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

317 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record